Royalty Pharma plc Form 4 Filings

Royalty Pharma plc (RPRX) EVP, Research & Investments Marshall Urist sold 4,126 Class A Ordinary Shares on September 28, 2026, at $57.88 per share under a Rule 10b5-1 plan adopted June 26, 2026. After the sale, he reported 4,126 shares held directly and 19,020 shares held indirectly through an IRA.

Separately, Urist and family vehicles controlled by him reported limited partnership interests exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd. exchangeable into 1,356,528 Class A Ordinary Shares. The Class E Ordinary Shares are subject to vesting conditions.

At Royalty Pharma plc, EVP & Chairman, Partnering Christopher Hite reported that SCH Investment Partners LLC sold 100,000 Class A ordinary shares on September 22, 2026: 96,073 at a weighted average $58.5148 per share and 3,927 at $58.9261. The sales were made under a Rule 10b5-1 plan adopted March 20, 2026. Hite held 23,200 shares directly after the transactions; family vehicles also hold interests exchangeable into 866,410 Class A ordinary shares and Class E shares exchangeable into 1,238,789 Class A ordinary shares, with vesting conditions applying to the Class E shares.

Royalty Pharma plc (RPRX) reported insider activity by Christopher Hite, EVP & Chairman, Partnering. An entity associated with him, SCH Investment Partners LLC, sold 100,000 Class A Ordinary Shares at a weighted average price of $59.9725 per share pursuant to a Rule 10b5-1 trading plan, leaving 370,401 indirectly held shares. Separately, Hite made a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University, after which he directly held 23,200 shares. Family vehicles also hold exchangeable interests and Class E shares that are convertible into additional Class A Ordinary Shares, some of which are subject to vesting conditions.

Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported selling a total of 11,002 Class A Ordinary Shares of RPRX on August 13, 2026 in open-market or private transactions under a Rule 10b5-1 plan adopted on February 24, 2026. The sales comprised 9,230 shares at a weighted average price of $58.5864 (with individual trades between $57.99 and $58.98) and 1,772 shares at a weighted average price of $59.1415 (with trades between $58.98 and $59.52). Following these transactions, indirect holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in the reporting person’s IRA, and 1,450 shares held by the spouse, plus 1,500 shares held directly. In addition, the reporting person and related family vehicles hold interests exchangeable into 6,448,180 Class A Ordinary Shares via limited partnership interests in RPI US Partners 2019, LP and 1,788,777 Class A Ordinary Shares via Class E Ordinary Shares of Royalty Pharma Holdings Ltd, which are subject to vesting conditions.

Pablo G. Legorreta, CEO and Chairman of Royalty Pharma, reported an exempt award of 65,216 Class A Ordinary Shares in settlement of Equity Performance Awards, bringing his direct Class A stake to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares; these limited partnership interests may be exchanged into Class A at no additional cost under an exchange agreement. The filing also notes substantial indirect holdings through family entities and trusts, including 9,700,000 Class B and 13,356,742 Class E shares that are exchangeable into Class A, with Class E subject to vesting conditions.

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported two equity changes. On August 5, 2026, an exempt acquisition under Rule 16b-3 delivered 11,002 Class A Ordinary Shares through settlement of Equity Performance Awards to TPC RP EPA1 LLC. On August 7, 2026, an indirect bona fide gift transferred 18,500 Class E Ordinary Shares, leaving 1,788,777 Class E shares indirectly held; these Class E shares are subject to vesting and are ultimately convertible into Class A Ordinary Shares. Coyne and related vehicles also hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares, plus additional direct and indirect Class A positions.

Hite Christopher reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc executive Christopher Hite, EVP & Chairman, Partnering, received an exempt grant of 11,002 Class A Ordinary Shares on 2026-08-05 in connection with settlement of Equity Performance Awards, held indirectly through SCH Investment Partners LLC, bringing that entity’s holdings to 470,401 shares. He also holds 40,000 Class A Ordinary Shares directly, while family vehicles controlled by him hold limited partnership interests exchangeable into 866,410 additional Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, which are subject to vesting conditions.

Royalty Pharma plc executive Urist Marshall reported two insider equity movements. He received 8,252 Class A Ordinary Shares as an exempt award tied to Equity Performance Awards and indirectly made a bona fide gift of 3,000 limited partnership interests exchangeable into 30,000 Class A shares. He also holds Class A shares indirectly through an IRA and Class E Ordinary Shares that are exchangeable into 1,356,528 Class A shares, subject to vesting conditions.

Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares. The shares were sold on July 1, 2026 at a weighted average price of $55.8802 per share in multiple trades within a disclosed price range. The filing states that all reported transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. After this sale, Urist reports no directly held Class A shares and an indirect holding of 19,020 shares through an IRA.

Royalty Pharma plc executive Christopher Hite reported pre-planned open-market sales of 130,000 Class A Ordinary Shares on June 30, 2026 under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices generally between about $56 and $57 per share.

After these transactions, Hite holds 40,000 Class A Ordinary Shares directly. Additional shares are held indirectly through SCH Investment Partners LLC, which reported post-transaction ownership of 459,399 Class A Ordinary Shares. Some of the sales in this filing were executed by that LLC rather than by Hite personally.

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an award of 689 Class A Ordinary Shares, valued at $54.3998 per share. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a quarterly cash retainer of $37,500.

After this equity award, Bassler directly holds 79,181 Class A Ordinary Shares. This transaction reflects compensation paid in stock rather than cash, and does not represent an open-market purchase or sale.

Royalty Pharma plc EVP Marshall Urist reported an open-market sale of 9,098 Class A Ordinary Shares of RPRX at a weighted average price of $55.1843 per share. After this transaction, he directly holds 9,099 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, meaning the trades were scheduled in advance rather than timed discretionarily.

Royalty Pharma plc executive Christopher Hite reported pre-planned insider sales linked to an affiliated entity. On June 23, 2026, SCH Investment Partners LLC, an entity associated with Hite, sold a total of 150,000 Class A Ordinary Shares in open-market transactions at weighted average prices of $54.47 and $54.11 per share.

All transactions were executed under a Rule 10b5-1 trading plan adopted on March 20, 2026, indicating they were scheduled in advance. Following these sales, SCH Investment Partners LLC held 559,399 Class A Ordinary Shares indirectly for Hite, while he also held 70,000 shares directly.

Royalty Pharma plc director Elizabeth H. Weatherman received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The grant was made at no cash cost to her and is classified as a compensation-related acquisition, not an open-market purchase.

The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award agreement. After this grant, she holds 13,103 shares directly.

Norden Gregory reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Gregory Norden received a new equity grant. On June 5, 2026, he was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units at a price of $0.00 per share under the company’s 2020 Independent Director Equity Incentive Plan.

The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholders’ meeting, subject to plan and award terms. Following this grant, Norden directly holds 196,348 Class A Ordinary Shares.

LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the company’s 2020 Independent Director Equity Incentive Plan. These units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholder meeting, subject to plan and award terms. Following this grant, Love directly holds 58,393 Class A Ordinary Shares.

Royalty Pharma plc director David C. Hodgson reported an acquisition of 4,545 restricted stock units linked to Class A ordinary shares as equity compensation. The award was granted under the company’s 2020 Independent Director Equity Incentive Plan and is scheduled to vest 100% on the earlier of one year from grant or the next annual shareholder meeting. The restricted stock units are held solely for the benefit of General Atlantic Service Company, L.P., and Hodgson disclaims beneficial ownership of the underlying shares. Following this grant, 37,873 Class A ordinary shares are reported as directly held.

Ho Carole reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Carole Ho reported a grant of 4,545 Class A Ordinary Shares in the form of restricted stock units. The award was made at a price of $0.00 per share as compensation and is scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award terms. Following this grant, Ho holds 4,545 shares directly and 8,558 shares indirectly through the Rohatgi-Ho Family 2009 Revocable Trust, where she serves as trustee.

Engelbert Catherine M. reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Catherine M. Engelbert received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The award was granted at no cash cost to her and was made under the company’s 2020 Independent Director Equity Incentive Plan.

The restricted stock units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of shareholders, subject to plan and award terms. Following this grant, Engelbert directly holds 55,673 Class A Ordinary Shares.

Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Vlad Coric received an equity award of 4,545 Class A Ordinary Shares at no cost, reported as a grant under the company’s 2020 Independent Director Equity Incentive Plan. The award consists of restricted stock units scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the plan and award terms. Following this grant, Coric directly holds 15,343 Class A Ordinary Shares.

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. These units were granted at no cash cost and increase her directly held position to 78,492 shares.

The award was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan and is generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to plan and award terms. This is a routine, compensation-related grant rather than an open-market share purchase or sale.

Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported an open-market sale of 64,399 Class A Ordinary Shares on May 26, 2026 at a weighted average price of $53.9778 per share, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, that entity held no remaining shares, while other reported direct and indirect accounts continued to hold Class A Ordinary Shares.

Royalty Pharma plc EVP Marshall Urist reported an open-market sale of Class A Ordinary Shares. On May 20, 2026, he sold 13,684 shares at a weighted average price of $52.7505 per share in multiple transactions between $52.62 and $52.96.

After the sale, Urist directly owned 18,197 Class A Ordinary Shares and indirectly owned 19,020 shares through an IRA. All reported transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating a scheduled disposition rather than an opportunistic trade.

Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026.

Following the sale, Urist directly holds 31,881 Class A Ordinary Shares and indirectly holds 19,020 shares through an IRA. The sale price reflected multiple transactions within a range of $52.88 to $53.25 per share.

Royalty Pharma plc director Gregory Norden reported an open-market sale of Class A Ordinary Shares. On May 14, 2026, he sold 3,045 shares at $53.00 per share. After this transaction, he directly holds 191,803 Class A Ordinary Shares.

The filing notes the trade was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating the sale timing was scheduled in advance rather than decided opportunistically.

Royalty Pharma plc director and CEO Pablo G. Legorreta received 143,821 Class A Ordinary Shares as an equity award. The shares were granted at $0.00 per share in connection with the settlement of Equity Performance Awards and are described as an exempt acquisition under Rule 16b-3. Following this grant, Legorreta directly holds 1,240,604 Class A Ordinary Shares. He also has indirect holdings through family members and related entities, including 1,040,410 shares held by the Legorreta Children 2002 Trust and 901,590 shares held by the GST-Exempt Legorreta 2012 Family Trust. The filing does not show any open-market purchases or sales, indicating a routine compensation-related share award rather than a discretionary trade.

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported an exempt acquisition of Class A Ordinary Shares through an affiliated entity. On May 6, 2026, TPC RP EPA1 LLC, an entity associated with him, received 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.

Following this award, TPC RP EPA1 LLC held 64,399 Class A Ordinary Shares indirectly. Additional holdings reported as of the same date include 1,500 shares held directly, 1,450 held indirectly by spouse, 23,270 held indirectly by IRA, and 24,170 held indirectly by spouse’s IRA.

Royalty Pharma plc executive Christopher Hite reported an exempt equity award rather than an open-market trade. On May 6, 2026, an entity associated with him, SCH Investment Partners LLC, acquired 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards, treated as exempt under Rule 16b-3. Following this award, SCH Investment Partners LLC held 709,399 Class A Ordinary Shares indirectly. A separate entry shows 70,000 Class A Ordinary Shares held directly as of the same date, recorded as a holding entry without a reported purchase or sale.

Urist Marshall reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc EVP Marshall Urist received a stock grant of 18,197 Class A Ordinary Shares on an exempt basis under Rule 16b-3, in connection with the settlement of Equity Performance Awards. The shares were awarded at no cash cost, increasing his direct holdings to 45,565 Class A Ordinary Shares, in addition to 19,020 shares held indirectly through an IRA.

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of a total of 34,791 Class A Ordinary Shares on April 28, 2026. The shares were sold at a weighted average price of $49.7784 per share through entities TPC RP EPA1 LLC and TPC RP 2021, LLC, under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. Following the transactions, TPC RP EPA1 LLC held 40,136 Class A Ordinary Shares, while TPC RP 2021, LLC held none, and the filing also lists additional direct and IRA-related holdings for Coyne and his spouse.

Royalty Pharma plc EVP & CFO Terrance P. Coyne, through affiliated entities, reported planned open-market sales of Class A Ordinary Shares. On April 1, 2026, TPC RP EPA1 LLC sold 1,875 shares and TPC RP 2021, LLC sold 32,916 shares at a weighted average price of $48.3318 per share, all under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP EPA1 LLC held 42,011 shares and TPC RP 2021, LLC held 32,916 shares. Additional holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in an IRA, 1,500 shares held directly, and 1,450 shares held by a spouse, indicating that the transactions represent a partial reduction of a larger overall position.

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an equity grant of 815 Class A Ordinary Shares. The award was made on a grant/award basis at a reference price of $45.977 per share and was issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a $37,500 quarterly retainer payment. Following this grant, Bassler directly holds 73,947 Class A Ordinary Shares.

Royalty Pharma plc reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares of the company. On March 23, 2026, TPC RP 2021, LLC sold 32,916 shares and TPC RP EPA1 LLC sold 1,875 shares in open-market transactions at a weighted average price of $45.5287 per share, with individual prices ranging from $45.30 to $45.94.

All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP 2021, LLC held 65,832 shares and TPC RP EPA1 LLC held 43,886 shares, and Coyne also reported additional indirect and direct holdings through various IRA and family accounts.

Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.

Royalty Pharma plc insider reporting shows entities associated with EVP & CFO Terrance P. Coyne selling Class A Ordinary Shares of the company. On the reported date, TPC RP 2021, LLC and TPC RP EPA1 LLC together sold 34,791 shares in open-market transactions at a weighted average price of $45.3165 per share.

The filing notes these transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2025, which automates sales based on preset instructions. A footnote explains the reported sale price is an average, with individual trades executed between $44.97 and $45.60 per share.

Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share on February 11, 2026 through the settlement of equity performance awards. Following this exempt award, he directly holds 1,098,783 Class A Ordinary Shares.

He also has indirect ownership through various family trusts and entities, including Legorreta Children 2002 Trust, GST-Exempt Legorreta family trusts, Legorreta Investments LLC, Tata MC 35 Ltd., and accounts for spouse and children. In addition, he and related vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported an indirect equity award of Class A Ordinary Shares. On February 11, 2026, an affiliated entity, TPC RP EPA1 LLC, acquired 26,626 Class A shares at $0 per share in an exempt transaction under Rule 16b-3 tied to the settlement of equity performance awards. Following this grant, TPC RP EPA1 LLC holds 49,511 Class A shares indirectly for Coyne. The filing also notes additional indirect holdings through related LLCs and retirement accounts, plus partnership and Class E Ordinary Share interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the Class E interests subject to vesting conditions.

Royalty Pharma plc EVP & Vice Chairman Christopher Hite reported an indirect acquisition of 26,626 Class A Ordinary Shares on February 11, 2026. The shares were granted at $0 per share in an exempt equity award settlement under Rule 16b-3.

After this transaction, 685,136 Class A Ordinary Shares are held indirectly through SCH Investment Partners LLC, and 70,000 Class A Ordinary Shares are held directly. In addition, family vehicles hold interests exchangeable into 866,410 Class A shares and Class E shares exchangeable into 1,238,789 Class A shares, with the Class E shares subject to vesting conditions.

Royalty Pharma plc EVP Marshall Urist reported an exempt acquisition of 19,970 Class A Ordinary Shares on February 11, 2026. The shares were granted at a price of $0.00 in connection with the settlement of equity performance awards, increasing his directly held Class A stake to 27,368 shares. In addition, 19,020 Class A Ordinary Shares are held indirectly through an IRA, highlighting a mix of direct and retirement-account ownership tied to his role as EVP, Research & Investments.

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. Between February 2 and 4, 2026, TPC RP 2021, LLC and TPC RP EPA1 LLC sold multiple share blocks at weighted average prices around $42–$43 per share, with detailed price ranges disclosed in footnotes. All sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025. The filing also lists remaining indirect holdings in family vehicles and IRAs, direct holdings, and additional partnership and Class E interests exchangeable into Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.

Royalty Pharma plc executive Marshall Urist reported an automatic share sale under a pre-arranged trading plan. On January 30, 2026, an entity listed as Sandy Lamm LLC sold 20,000 Class A Ordinary Shares at a weighted average price of $41.0905 per share under a Rule 10b5-1 plan adopted on September 16, 2025.

After this sale, accounts associated with Urist continued to hold 19,020 Class A Ordinary Shares indirectly through an IRA and 7,398 Class A Ordinary Shares directly. The filing also notes additional exchangeable partnership and Class E ordinary share interests that could convert into Class A Ordinary Shares, subject to vesting conditions.

Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported a planned sale of Class A Ordinary Shares through an affiliated entity. On January 23, 2026, 20,000 Class A Ordinary Shares were sold by Sandy Lamm LLC, an entity associated with Urist, at a weighted average price of $40.2555 per share under a pre-established Rule 10b5-1 trading plan adopted on September 16, 2025.

Following this transaction, the filing shows indirect ownership of 20,000 shares through Sandy Lamm LLC, 19,020 shares held indirectly via an IRA, and 7,398 shares held directly. The filing also notes additional exchangeable interests and Class E Ordinary Shares in affiliated Royalty Pharma entities that can convert into Royalty Pharma plc Class A Ordinary Shares, with some of those Class E shares subject to vesting conditions.

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported automatic sales of Class A Ordinary Shares through entities associated with him. On January 20, 2026, TPC RP 2021, LLC sold 65,832 Class A shares at a weighted average price of $39.3484 per share, leaving 394,996 shares held indirectly by that LLC. On the same date, TPC RP EPA1 LLC sold 3,750 Class A shares at a weighted average price of $39.3484, with 36,010 shares remaining held indirectly by that LLC.

All reported sales were made under a Rule 10b5-1 trading plan adopted by Coyne on August 8, 2025, meaning they were pre-arranged. In addition, Coyne reports indirect holdings of Class A shares through a spouse’s IRA, his own IRA, and shares held by his spouse, as well as limited partnership and Class E Ordinary Share interests that are exchangeable for additional Class A Ordinary Shares, with some of those interests subject to vesting conditions.

Royalty Pharma EVP Marshall Urist, through Sandy Lamm LLC, sold 20,000 Class A Ordinary Shares of Royalty Pharma plc on January 16, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025. The shares were sold at a weighted average price of $39.5173 in multiple trades between $39.37 and $39.76 per share. Following the sale, Sandy Lamm LLC held 40,000 shares, an IRA associated with the reporting person held 19,020 shares, and 7,398 shares were held directly. In addition, the reporting person and family vehicles hold limited partnership and holding company interests exchangeable into 2,474,120 and 1,356,528 Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.

Royalty Pharma plc reported an insider transaction involving an entity affiliated with its EVP, Research & Investments, Marshall Urist. On January 9, 2026, Sandy Lamm LLC, an entity associated with Urist, sold 20,000 Class A Ordinary Shares at a weighted average price of $40.7817 per share pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2025. After this sale, 60,000 Class A Ordinary Shares were held indirectly through Sandy Lamm LLC, 19,020 shares were held indirectly through an IRA, and 7,398 shares were held directly.

Royalty Pharma plc’s EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. On January 2, 2026, TPC RP 2021, LLC sold 65,832 Class A shares and TPC RP EPA1 LLC sold 3,750 Class A shares, both at a weighted average price of $38.4157 per share, under a Rule 10b5-1 trading plan adopted on August 8, 2025.

After these trades, TPC RP 2021, LLC held 460,828 Class A shares and TPC RP EPA1 LLC held 39,760 Class A shares, reported as indirect holdings for Coyne. Additional indirect holdings include shares held through the reporting person’s and spouse’s IRAs and by the spouse, as well as partnership and Royalty Pharma Holdings Ltd interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the latter subject to vesting conditions.

Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported selling 20,000 Class A Ordinary Shares on December 16, 2025. The sale, coded as "S," was executed at a weighted average price of $38.321 per share, with individual trades ranging from $38.24 to $38.40. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.

Following this activity, Urist reports beneficial ownership of 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly. In addition, Urist and related family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into a further 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

Royalty Pharma plc executive vice president and chief financial officer Terrance P. Coyne reported selling Class A ordinary shares of Royalty Pharma plc on 12/15/2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows a sale of 65,832 Class A shares at a weighted average price of $38.3601 per share, with individual trades occurring between $38.10 and $38.48 per share.

After these transactions, Coyne continues to report indirect beneficial ownership of 526,660 Class A shares through TPC RP 2021, LLC and 43,510 Class A shares through TPC RP EPA1 LLC, along with additional holdings in IRA and spouse accounts. The remarks also state that entities controlled by him hold interests exchangeable into 6,448,180 Class A shares and Class E shares exchangeable into 1,807,277 Class A shares, with the Class E shares subject to vesting conditions.

Royalty Pharma plc (RPRX) EVP & CFO Terrance P. Coyne reported insider stock sales in a Form 4 filing. On 11/24/2025, multiple sales of Class A ordinary shares were executed, including 55,146 shares held indirectly through TPC RP 2021, LLC at a weighted average price of $38.6663 per share and 10,686 shares at a weighted average price of $37.9604 per share. Additional smaller sales were reported through TPC RP EPA1 LLC.

After these transactions, Coyne continues to hold significant indirect stakes, including 669,010 Class A ordinary shares via TPC RP 2021, LLC and 51,634 Class A ordinary shares via TPC RP EPA1 LLC, plus various IRA and spousal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A ordinary shares and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions. All reported sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025.